mediastinum for even peripheral clinical stage Ia tumors would require a high level of evidence that there was no chance of missing occult disease.
In the current issue of Annals of Surgical Oncology, Deng et al. 6 retrospectively analyzed 590 patients with cT1 a-c N0M0 peripheral NSCLC who underwent segmentectomy or lobectomy. They analyzed patterns of occult mediastinal lymph node metastasis. The study is predicated on the possibility that lobe-specific lymph node dissection (L-SLND) might yield less morbidity than systematic lymph node dissection (SLND), which may be unnecessary given the low rate of metastasis from peripheral stage Ia lesions. The authors categorized mediastinal lymph node zones into upper (stations 2R, 3, 4R on the right; stations 4L, 5, 6 on the left), subcarinal (station 7), and lower (stations 8 and 9). They identified a 9.5% overall rate of occult N2 disease.
Regarding the pattern of metastasis, the authors found that upper lobe tumors rarely metastasized outside of the upper LN zone (one station 7 and one station 9 metastasis for all upper lobe tumors bilaterally combined), and both of these were from tumors [ 2 cm. Lower lobe tumors had a more equal distribution of metastasis to all three LN zones, however only tumors [ 2 cm (T1c) metastasized to an upper LN zone. The authors concluded that L-SLND for upper lobe cT1a-b tumors includes only upper zone lymph node stations, while lower lobe cT1a-b tumors require only lower and subcarinal LN zones.
Several points merit discussion to understand the current paradigm of managing peripheral cT1N0 NSCLC. First, it is well-established that the yield of occult N2 disease, especially that which is accessible by mediastinoscopy, is extremely low (3-6%), and thus is typically and reasonably omitted. For the same reason, we generally omit positron emission tomography scans for cT1 peripheral tumors without computed tomography-positive mediastinal lymph nodes. As mentioned previously, the question as to whether a lymph node dissection increases operative morbidity was evaluated in a randomized controlled trial and none was found. 5 It is also worth noting that the author's 9.5% rate of occult N2 disease is higher than previous reports. 6 In a series from the Mayo Clinic that analyzed 945 patients with cT1N0 NSCLC, only a 3.7% rate of occult N2 disease was identified at the time of surgery. 2 Additionally, this study included both peripheral and central tumors, the latter of which is more prone to metastasis to the mediastinum.
The current study is an excellent step forward to understanding the rates and pattern of metastasis of earlystage peripheral tumors, an entity we are fortunate to manage with increasing frequency owing in part to increased rates of lung cancer screening. They also identify what we know to be true about tumor biology, i.e. that tumor size is correlated with the propensity/ability to metastasize. As such, it appears that even within clinical T1 NSCLC, there are differences between T1a, T1b, and T1c tumors in terms of patterns and rates of metastasis. Future randomized controlled trials are needed to better understand this phenomenon and help guide our work-up and intraoperative management of these patients.
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